The procedure used matches the standard procedure at the Dutch SII, in which the LE receives the report made in the RTW process and the instruction to assess the RTW efforts.
Toxicity was assessed using the ApoTox-Glo Triplex Assay (Promega Madison WI) according to the manufacturer's instruction to assess viability, cytotoxicity, and apoptosis events, with no toxicity identified at the tested concentrations.
Human VEGF ELISA kit (EuroClone, Paignton, UK) was used according to the manufacturer's instructions to assess levels of the cytokine in serum samples.
WST-1 assay (Biovision Research Products, CA, USA) was conducted as per manufacturer's instructions to assess cellular proliferation over the culture period.
During the analysis period, daily measurements were made for BMD and BMC following the manufacturer's instructions, to assess the long-term reproducibility of the measured parameters quality control (QC).
Serum TRACP 5b level was measured by a solid phase immunofixed enzyme activity assay (Rat TRACPTM Assay, IDS Inc., Fountain Hills, AZ, USA) according to the manufacturer's instructions to assess bone resorption.
Serum TRACP 5b level was measured by a solid phase immunofixed enzyme activity assay (Rat TRACP™ Assay, IDS Inc., Fountain Hills, AZ, USA) according to the manufacturer's instructions to assess bone resorption.
The treatment control item was adapted as per published instructions to assess perceived helpfulness of each specific treatment component (insulin, blood pressure pills, cholesterol pills, diet, and exercise) separately for diabetes and for preventing heart disease.
Other biomarkers were measured using commercial ELISA kits according to manufacturer's instructions to assess the astrocyte marker glial fibrillary acidic protein (GFAP; BioVendor, Brno, Czech Republic) and S100b for astroglial cells (BioVendor), neuron-specific enolase (NSE; USCN, Hubei, China), and total tau protein for axonal/neuronal damage (Invitrogen, Carlsbad, CA).
Enzyme-linked immunosorbant assays (ELISAs) were performed on the supernatant of BAL fluid following manufacturer's instructions to assess the presence of pro-MMP9 and the cytokines IL-6 and tumor necrosis factor-α (TNF-α) (ELISA kits from R&D Systems, Minneapolis, MN).
The respective conceptualization is typically implied in the instructions used to assess goal orientation.
